header logo image


Page 819«..1020..818819820821..830840..»

Trump expected to sign PACT Act – Fence Post

November 11th, 2019 11:45 am

President Trump is expected to sign the Preventing Animal Cruelty and Torture, or PACT, Act after it passed unanimously through the Senate. If signed, the bill would make animal cruelty a federal felony. H.R.724 was introduced by Rep. Ted Deutch, D-Fla., in January of 2019.

The bill, according to Danielle Beck, National Cattlemens Beef Associations senior director of governmental affairs, has 301 co-sponsors, including 216 Democrats and 85 Republicans. A companion bill (S. 479) was introduced by Sen. Pat Toomey, R-Pa., last February, and has 41 co-sponsors in total (33 Democrats, six Republicans and two Independents). H.R. 724 passed the House on Oct. 22, 2019, by a voice vote and passed in the Senate without amendment by unanimous consent earlier last week.

The bill revises and expands criminal provisions with respect to animal crushing, defined as conduct in which one or more living non-human mammals, birds, reptiles, or amphibians is purposely crushed, burned, drowned, suffocated, impaled, or otherwise subjected to serious bodily injury. Current federal law prohibits fighting and criminalizes animal cruelty only if the wrongdoers create and sell videos of the act, under the 2010 Animal Crush Video Prohibition Act. Under the PACT Act, those convicted could face seven years in prison and fines on federal felony charges.

The legislation contains exceptions for customary and normal veterinary, agricultural husbandry, or other animal management practice; the slaughter of animals for food; hunting, trapping, fishing, a sporting activity not otherwise prohibited by Federal law, predator control, or pest control; medical or scientific research; conduct necessary to protect the life or property of a person; or performed as part of euthanizing an animal.

Now is the time to engage animal health officials and professionals for a true determination of animal welfare issues on livestock production units.

In an article released by Protect the Harvest, there are already laws against animal cruelty in all 50 states. Additionally, subjective language like common practices can be left open to interpretation.

According to the release, practices employed by veterinarians and producers that are standard and necessary could be misunderstood by someone inexperienced in production agriculture or veterinary medicine. Under the vague language of the bill, Protect the Harvest said some common practices could be misinterpreted based on the bills language.

Terry Fankhauser, executive vice president of the Colorado Cattlemens Association, said he hopes the act will create a hard stop on additional state and national legislation that is inconsistent and ill-conceived, while the PACT Act will allow for swift and strong prosecution of those who are willfully abusing animals.

Now is the time to engage animal health officials and professionals for a true determination of animal welfare issues on livestock production units, he said. It is our hope the act will employ the resources necessary to implement this at state level.

Gabel is an assistant editor and reporter for The Fence Post. She can be reached at rgabel@thefencepost.com or (970) 392-4410.

Link:
Trump expected to sign PACT Act - Fence Post

Read More...

Teacher saves caged puppy from drowning in Illinois lake – WIFR

November 11th, 2019 11:45 am

CHAMPAIGN, Ill. (AP) -- A teacher who rescued a caged puppy from drowning in a cold central Illinois lake over the weekend says the dog had been clearly abused.

Bryant Fritz, who teaches middle school science at Next Generation School in Champaign, was preparing to fish Saturday when he found a black and white puppy submerged in rising water and trapped inside of a dog crate in Kaufman Lake.

Fritz told The News-Gazette on Sunday that he waded into waist-high, freezing water in the Champaign lake before reaching the cage.

It was pretty clear the dog had been in the cold water for several hours. I immediately pulled her out of the water and dragged the crate to the shore, he said.

He then realized the dog had other medical issues.

When I got her up to the shore, there was blood all over the place, Fritz said. She was missing a bunch of fur on the back side, and the bottom of her paws were missing skin. She probably weighed 15 to 20 pounds; she was definitely a puppy. She was shaking so bad. Her eyes were shut. She was so miserable.

He took the dog to his truck, turned up the heat as high as he could and headed to the University of Illinois Veterinary Hospital, where he had called ahead to staff to let them know he was coming. On the way, he stopped at his house to wrap the puppy in a blanket to get her as warm as possible.

University of Illinois College of Veterinary Medicine spokeswoman Chris Beuoy noted the puppy has been responding favorably to treatment for hypothermia. The hospitals staff also cleaned the wounds and put her on antibiotics and pain medicine.

We werent sure if the dog would need additional care for her wounds, but she received more treatment for her wounds on Sunday, Beuoy said.

After Champaign County Animal Control takes custody of the pooch, Fritz hopes that he will be allowed to adopt her and give her a loving home.

As I filled out the paperwork when I brought her to the hospital, I realized I wanted this dog to be a part of my life, the teacher said.

See the original post:
Teacher saves caged puppy from drowning in Illinois lake - WIFR

Read More...

Cannabis topicals and your pet – Leafly

November 11th, 2019 11:45 am

In fact, cannabis therapy actually does appear positive for animals, according to Dr. Sarah Silcox, an Ajax, ON-based veterinarian and president of the Canadian Association of Veterinary Cannabinoid Medicine (CAVCM).

The problem is, prescribing cannabis for pets isnt legal in Canada (yet).

While many veterinarians are supportive of using cannabis as part of the total treatment plan, many people dont realize that legally, veterinarians cannot authorize (prescribe) medical cannabis. And this puts them in a very difficult spot, says Silcox.

Surprised? Well, dogs just arent the litigious type: legal pressure by human patients put the original medical cannabis regulations into effect. Then, when the Cannabis Act came along, Silcox explains existing medical regulations were simply rolled into the new cannabis regulations, without consideration of our animal friends. To date, there is no legal framework for animal care providers until the Cannabis Act is reviewed again in 2022.

While vets cannot prescribe cannabis, many are open to advising on treatment options you could independently provide for your pet. Just dont play Doc McStuffins on your own: Silcox warns administering cannabis without some guidance can pose serious adverse effects and potential drug interactionseven pure CBD.

Here, she plays out a few scenarios:

Not really. The biggest concern surrounds the risk of your pet licking the cream off, she explains. Not only will fur likely get in the way (wasting your product), when your pet licks or grooms the area they risk ingesting something meant to be used externally. Its not just the THC, other cannabinoids or terpenes she worries about, but potential effects from other compounds found inside the topical. If you have a topical that you think could help your pet feel better, bring it in to your vet for advice.

Again, its about the side effects and possible drug interactions that pose a risk. However, this is not to say you cant discuss CBD with your vet. While Silcox says there arent published studies on CBD for treating cats specifically, she says they do appear to tolerate CBD well. Talking to your vet will ensure the product youre using is safe and that the dose is appropriate. Your veterinarian may also want to do some testing to ensure there are no underlying physical causes to your pets behaviour changes, she adds.

Maybe. Seizures, along with chronic pain, age-related changes, sleep disturbances, and cancer are the most common reasons people request cannabis therapy for their pets, according to Silcox. Again, while they cant yet prescribe, veterinarians can discuss cannabis therapy as an option and help monitor the outcome.

In this emerging area of medicine, documentation is important for many reasons. We want to track any unexpected effects, document your pets response to treatment, and learn from each case in the hopes that it will help other patients that follow.

She says cannabis remains a viable option for treating pets, especially when other available treatments are not effective. This is why the CAVCM and the Canadian Veterinary Medical Association (CVMA) have been advocating to change current regulations.

Whether its a ripped dewclaw, sore joints, or something more serious, work with your vet to find the right cannabis therapy for your furry loved one. And if its important enough, Silcox encourages you to let your MP know you support changes to the Cannabis Act allowing veterinarians to authorize medical cannabis.

Colleen Fisher Tully is a freelance writer and editor with recent work in Clean Eating, Today's Parent, The Walrus and Local Love. She posts random thoughts on Twitter @colleenftully

Go here to read the rest:
Cannabis topicals and your pet - Leafly

Read More...

‘Grandma Joy,’ grandson share photos of US as they try visiting all national parks – msnNOW

November 11th, 2019 11:45 am

Courtesy Brad Ryan Brad Ryan and his grandmother Joy have spent the last four years traveling more than 40,000 miles and visiting 49 national parks in 41 states including the Gateway Arch, Hot Springs, Big Bend and Death Valley.

For the last four years, Brad Ryan and his grandmother Joy Ryan have been on the road trip of a lifetime, attempting to visit all 61 national parks and inadvertently giving all of us a true tour of the U.S. in all of its natural beauty.

So far, the pair have traveled 40,000 miles through 41 of the lower 48 states and taken in the scenery at 49 national parks.

On Friday, they were wrapping up a trip to Gateway Arch National Park in St. Louis -- their 49th and final park in the lower 48 states.

Before Gateway, there was the Grand Canyon, Yellowstone, Joshua Tree, Glacier National Park and even Redwood National Park.

"It is breathtaking," Joy Ryan, 89, told ABC News recently from the Santa Elena Canyon in Texas' Big Bend National Park. "All of these people are really enjoying it."

(MORE: Grandson on a mission to take his small-town grandma to every national park)

"We'll have to come back here and explore it some time," Brad Ryan said.

The duo started in 2015 and were at Great Smoky Mountains National Park in Tennessee when Joy Ryan, then 85, spent the first night in a tent.

Brad Ryan, 38, said she'd spent the majority of her life in the tiny town of Duncan Falls, Ohio.

"She had never camped a night in her life," he told ABC News previously. "When we arrived at 1 a.m. in the rain...she held the umbrella over my head while I put the tent together."

At the time, Brad was a fourth-year veterinary student at the Ohio State University College of Veterinary Medicine, but he said he needed a break.

(MORE: 83-year-old grandmother wins hearts as the flower girl at her granddaughters wedding)

"I remembered a prior conversation with my Grandma Joy when we [were] discussing my 2009 Appalachian Trail hike from Georgia to Maine, and she expressed regret that she had never seen the mountains and explored the great outdoors throughout her life. So, I invited her to join me on my weekend escape to the Smokies," he told ABC News in a previous interview.

Big Bend National Park was the 47th U.S. national park for the duo.

"We can't believe that we're closing in on that 61 national park goal and we're having a wonderful time here in Texas," Brad Ryan told ABC News. "This is definitely one of the prettiest parks that we've seen so far. Big Bend National Park has Badlands. It has canyons. It has the mighty Rio Grande River, and so much wildlife and beautiful fauna and flora that we really feel like we might have to come back for a second go."

(MORE: Bride and groom have their 4 grandmothers serve as flower girls at their wedding)

"We've met some wonderful people," Joy Ryan added. "Everywhere you look you see something beautiful. ... This is a great place."

On Friday, Joy Ryan said she was ready to take a much-needed break before the next adventure.

"I am ready," she said, "to go home, kick back my heels and sit down and rest a minute."

See the original post:
'Grandma Joy,' grandson share photos of US as they try visiting all national parks - msnNOW

Read More...

Top stories: The archaeology of slavery, superproductive corn, and how NOT to train your dog – Science Magazine

November 11th, 2019 11:44 am

(Left to right): M. CANTWELL/SCIENCE; OTICKI/SHUTTERSTOCK.COM; CHRISTOPHERBERNARD/ISTOCK.COM

By Eva FrederickNov. 8, 2019 , 4:20 PM

Caribbean excavation offers intimate look at the lives of enslaved Africans

To an outsider, the archaeological finds from Estate Little Princess in the U.S. Virgin Islandsfish and pig bones from centuries-old meals, buttons that fell off clothing, bits of coarse local potterymight not look like much. But to archaeologists, they are treasures that offer an intimate look into some of the most enigmatic lives in modern history: those of the enslaved Africans who once lived there.

New genetically modified corn produces up to 10% more than similar types

Genetic engineering proponents have long promised the technology will help meet the worlds growing demand for food. But despite the success of genetically modified pest -resistant crops, scientists havent had much success with boosting crop growth. Now, researchers have shown for the first time that they can increase corn yields up to 10% by changing a gene for plant growth.

Bad dog? Think twice before yelling, experts say

Few things are more adorableor destructivethan a new puppy. When they pee on rugs, chew furniture, and get aggressive with other pups, their stressed-out owners usually turn to dog training. Now, a novel study suggests programs that use even relatively mild punishments like yelling and leash-jerking can stress dogs out, making them more pessimistic than dogs that experience reward-based training.

What do you see when you look at these photosanimals or humanmade objects?

Live in the urban jungle long enough, and you might start to see thingsin particular, humanmade objects like cars and furniture. Thats what researchers found when they melded photos of artificial items with images of animals and asked 20 volunteers what they saw. The people, all of whom lived in cities, overwhelmingly noticed the manufactured objects as the animals faded into the background.

Colombian womans genes offer new clues to staving off Alzheimers

In 2016, a 73-year-old woman from Medelln, Colombia, flew to Boston so researchers could scan her brain, analyze her blood, and pore over her genome. She carried a genetic mutation that had caused many in her family to develop dementia in middle age. But for decades, she had avoided the disease. The researchers now report that another rare mutationthis one in the well-known Alzheimers disease risk gene APOEmay have protected her.

Read more here:
Top stories: The archaeology of slavery, superproductive corn, and how NOT to train your dog - Science Magazine

Read More...

The world’s banana crops are under threat from a deadly fungus. Is gene editing the answer? – National Post

November 11th, 2019 11:44 am

We expect to have more than one variety of apple to choose from. Even at the most modestly stocked produce stand, youre likely to see mounds of Galas, McIntoshes and Honeycrisps. When it comes to the banana, though no matter where you shop theres only ever one: The Cavendish.

As far removed as we are from tropical growing regions, youd be forgiven for assuming the fruit we recognize as a cheap and reliable staple is the one true banana. In reality, however, there are over a thousand types, each exhibiting a different flavour profile, texture, shape, colour, ripening pattern and durability. And for the second time in recent history, the very existence of the sole breed we rely on which represents the single most exported fresh fruit on the planet is under threat.

Researchers, seeking a solution, are looking towards a new form of genetic modification. Could specific alterations of the genetic makeup of the Cavendish help stave off the disappearance of such a critical commodity?

In August, Colombia declared a state of emergency when scientists confirmed a banana-killing fungus had reached the Americas for the first time. Known by its common name, Panama disease, the strain of fungus Fusarium oxysporum cubense Tropical Race 4 (TR4) has been a known issue since the early 1990s, but until this year, it was largely contained to Asia. Immune to pesticides, the lethal soil-borne organism, for which there is no known cure, obliterates yields by choking banana trees of essential water and nutrients.

The Cavendishs predecessor as worlds presiding banana was the Gros Michel, a variety that dominated fruit stands in temperate regions until it was decimated by fungal strain Tropical Race 1 in the 1950s. That the extreme monoculture approach replicated with the Cavendish would result in a similar fate should have seemed inevitable.

Cavendish bananas are sterile and breeding them requires a cloning process that creates genetically identical plants. Because of their inherent lack of biodiversity, monocultures such as this banana are especially vulnerable to diseases and pests; when theres a weakness, such as little or no resistance against TR4, it can have sweeping and ruinous effects.

Given the bananas immense importance to producers and consumers, researchers have been attempting a variety of methods to create a resistance to the deadly fungus. According to Nature, James Dale, a biotechnologist at Queensland University of Technology in Brisbane, is currently field testing genetically modified bananas in Northern Australia with some success. Dale has added a gene from a wild banana into the Cavendish variety that makes it more resistant to the TR4.

However, even if scientists are able to breed a TR4-immune Cavendish, they wouldnt be permitted to grow or sell them in a significant portion of the world. In Europe, for example, GM crops are restricted. And in Canada, although GMOs have been on the market since the late 1990s, nearly 90 per cent of Canadians believe they should be subject to mandatory labelling.

As a result, researchers like Dale and Leena Tripathi, from the International Institute of Tropical Agriculture in Kenya, have begun experimenting with CRISPR technology. Where GMOs have a foreign gene inserted into the organism, CRISPR allows for the organisms genes to be edited. In the case of Dale, hes discovered a dormant gene in the Cavendish he hopes to activate.

The technique is perhaps best described by Jennifer Kuzma, co-director of the Genetic Engineering and Society Center at North Carolina State University. In an interview with Gastropod, she likened DNA to a book and CRISPR to a pen: You can go in and you can edit the letters in a word, or you can change different phrases, or you can edit whole paragraphs at very specific locations.

CRISPR and GMO are further differentiatedin terms of consumer perception. As a December 2018 study published in Global Food Security found, 47 per cent of Canadian respondents were willing to eat both GM and CRISPR foods, but participants across the board (in Australia, Belgium, Canada, France and the U.S.) were more apt to eat CRISPR than GM food.

Nevertheless, editing the genes of the banana is still in the early stages. Dale told Nature that itll be a couple of years before these get into the field for trials. Can the Cavendish banana wait that long?

In a recent interview with KCRW, Dan Koeppel, author of Banana: The Fate of the Fruit that Changed the World, said I think the time has come to stop looking at bananas as just one kind of fruit when there are thousands. Just as the range of apples at our fingertips is rich and getting richer, perhaps all the different varieties of bananas will prove ripe for discovery.

Follow this link:
The world's banana crops are under threat from a deadly fungus. Is gene editing the answer? - National Post

Read More...

Glowing with the flow – Harvard School of Engineering and Applied Sciences

November 11th, 2019 11:44 am

In the battle against heart disease, more than 400,000 coronary artery bypass grafting surgeries are performed in the U.S. each year.

While veins from a patients leg are often used in the surgical procedure, tissue-engineered vascular grafts (TEVG), which are grown outside the body using a patients endothelial cells, are proving to be an effective and increasingly popular technique.

The most common reasons for TEVG failure are conditions like blood clots, narrowing of the blood vessels, and atherosclerosis. But what if these grafts could be engineered to detect and even prevent those ailments from occurring?

A team of Harvard John A. Paulson School of Engineering and Applied Sciences students set out to answer that question for their project in this years International Genetically Engineered Machine Competition. The project, dubbed FlowGlo, seeks to use receptors that exist within the walls of human blood vessels to detect shear stress, a warning sign that a blood vessel may be narrowing.

Shear stress is important to detect because it is a marker of a lot of different cardiovascular diseases. When there is narrowing of a blood vessel due to a blood clot, shear stress jumps exponentially, maybe up to 10 times its normal level, said Teagan Stedman, S.B. 22, a bioengineering concentrator. Our idea is to link the activation of these receptors due to some level of shear stress to a modular response.

Shear stress is a function of viscosity and how rapidly different layers of fluid are flowing over each other through a blood vessel. Because the walls of the vessel must move and roll with the strain of blood flow, receptors naturally activate at different levels of shear stress.

For instance, when shear stress rises above 4 Pascals, channels open in one specific protein receptor, Piezo1, and calcium ions enter the cell, signaling the activation. The students engineered Piezo 1 and two other protein receptors to present different colored fluorescent proteins when that activation occurs.

Down the road, instead of using a fluorescent protein, you could possibly swap it out so the cells secrete some kind of clot busting protein to break up the clot and treat it on site, said Patrick Dickinson, A.B. 22, an applied math concentrator. Current clot-busting medication is delivered through an IV, and it is system-wide and much less targeted, so there are greater risks for side effects. We think this could be a more targeted treatment in the long run.

As part of their project, the team gathered feedback from Elena Aikawa, Professor of Medicine at the Harvard Medical School and Director of the Vascular Biology Program at Brigham and Womens Hospital, who studies tissue-engineered vascular grafts. They also conducted a survey to better understand public perception of genetic engineering ethics, since their technique would require engineered cells to be implanted in the human body.

As they gathered qualitative data, they worked long hours in the lab on intricate experiments. Since beginning the project this summer, the teammates overcame many challenges caused by the difficulty of cloning cells. Relying on the support of their mentor, Timothy Chang, a postdoctoral fellow in the lab of Pamela Silver at the Harvard Medical School, they brainstormed, troubleshot, and learned volumes about synthetic biology along the way.

I learned that biology is messy, Dickinson said. In a lab setting, there is a lot that is hard to predict. We certainly encountered a lot of frustration and stress along the way, but it was a good window into what research really is.

Now that the competition has concluded, the teams work will be included in the iGEM Registry of Standard Biological Parts, a repository of genetic parts that can be mixed and matched to build synthetic biology devices and systems.

For Rahel Imru, it is gratifying to know that future iGEM teams and research groups from around the world could someday build off the research she and her peers have done.

While the weeks leading up to the competition were a whirlwind, the experience was well worth the effort, said Imru, A.B. 21, a biomedical engineering concentrator.

This was my first lab experience, so I definitely learned a lot, she said. I look back and see how much weve grown. Maybe we didnt get all the data and results we wanted to by the end, but for the size of our team and the time that we had, seeing what we are able to accomplish is especially rewarding.

The rest is here:
Glowing with the flow - Harvard School of Engineering and Applied Sciences

Read More...

Five Reasons Why Its Never Too Late To Start A Business – Forbes

November 11th, 2019 11:44 am

PeakPx

Mark Zuckerberg founded Facebook when he was 19 years old. By 25, his company was valued at over $5 billion. At 28, he took Facebook public. Now, at the age of 35, he is among the top 10 richest people in the world.

When we think of entrepreneurs, we tend to think of the Mark Zuckerbergs of the world youthful visionaries who disrupt traditional businesses with a new and better ways of doing things.

New research, however, challenges the view that youth is advantageous to entrepreneurial success. Perhaps a better entrepreneurial archetype is that of Herbert Boyer. Boyer founded Genentech at the age of 40 based on his breakthrough discoveries in genetic engineering. Or, consider the story of David Duffield. Duffield founded Workday, a financial and human capital management software company, in his 60s, after spending a career in application software. Now, Workday has a market capitalization of over $40 billion.

The data is increasingly showing that its never too late to start a business. Below are five research-backed reasons why entrepreneurial success may come quickest to those who wait.

1) The stereotype of the very young and very successful entrepreneur is exactly that a stereotype.

It turns out that the media may be the biggest culprit in perpetuating the belief that entrepreneurship is a young mans game. For example, the website TechCrunch gives annual awards to the most compelling startups, internet and technology innovations of the year. The average age of award recipients from 2008 to 2016 was 31. Inc. magazine and Entrepreneur magazine also publish lists of entrepreneurs to watch. In 2015, the average age of entrepreneurs who made this list was 29. Compare that to the average age of a typical startup founder (42) to see the discrepancy.

2) Not only are older entrepreneurs more common, they are more successful.

42 is the average founder age of all S-corporations, C-corporations, and Partnerships that registered in the United States between 2007 and 2014. Examining the performance of these companies reveals yet another trend: companies with older founders tend to outperform companies with younger founders. Looking at the top 1% of startups (in terms of company performance), the average founder age increases to 43. Looking at the top 0.1%, the founder age increases even more, to 45. Moreover, the average age of startup founders who achieved a successful exit (as defined by an acquisition or an IPO) is 47.

3) Entrepreneurs working in major entrepreneurial hubs are no younger than other entrepreneurs.

Another misconception is that startup founders practicing in the hottest entrepreneurial hubs think Silicon Valley and New York City are younger than in other areas of the country. Again, the data does not show this to be the case. The average age of entrepreneurs in California, Massachusetts, and Silicon Valley is also 42. And, in New York City, the average entrepreneurial age is only one year younger than average (41).

4) The average age of new entrepreneurs entering the market over the past decade has increased.

Given the rise of technology and technology-related entrepreneurship, one might guess that the average entrepreneurial age has fallen in recent decades. Again, the data suggest the opposite. The average founder age has risen from 41.8 in 2007 to 42.5 in 2014.

5) Certain fields attract entrepreneurs that are older than average.

Not surprisingly, there is truth to the idea that technology is a young mans game. However, the age spread is not as wide as one might think. For instance, startup founders operating in the software publishing industry are, on average, 40 years old (two years younger than the overall average). That said, there are other fields that attract older entrepreneurs. For example, the average age of founders in the pipeline transportation of natural gas, basic chemical manufacturing, and paint, coating, and adhesive manufacturing industries are 51, 48, and 48, respectively. Startup founders operating in oil and gas extraction and engine, turbine, and power transmission equipment manufacturing are also significantly older than other types of entrepreneurs.

Conclusion. The novelist George Eliot famously said, Its never too late to be what you might have been. This is sage advice for all aspects of life, but it might be especially relevant in the case of entrepreneurship.

Link:
Five Reasons Why Its Never Too Late To Start A Business - Forbes

Read More...

Unraveling the mystery of Luther Burbank’s famous plums – Sonoma West

November 11th, 2019 11:44 am

A local scientist is sequencing the genomes of Burbanks plums to verify their history and create a genetic roadmap for future plant breeders

Luther Burbank is still a well-known name around Sonoma County it graces the regions largest arts center and a couple of public gardens. Burbank was Americas most famous horticulturalist (that is, someone who specializes in growing fruit, vegetables and flowers). Since he lived in a time when most Americans still made their living from agriculture, his discoveries seemed as vital and important as those of his contemporaries Thomas Edison and Henry Ford, both of whom visited him here in Sonoma County.

Luther Burbank died in 1926, and over the ensuing 93 years, his reputation has faded considerably, but the plants he created live on. An essay in the Journal of Heredity in 2006 estimated that Burbank introduced between 800 and 1,000 new plants to the American horticultural universe, including the Russet-Burbank potato (still the most common potato in America), Shasta Daisies, the Elberta peach and the luscious Santa Rosa plum.

With only a high school education and no scientific training, Burbank was a self-taught genius and a relentless experimenter, who, it turns out, took extremely poor notes. Still, Burbank filled a collection of notebooks with his large, ungainly scrawl, describing in the briefest of terms his plant breeding experiments. Many of these descriptions are accompanied by hatchmarks the meaning of which is still a mystery today and fruit prints, which he made by cutting a fruit in half and pressing it onto the page.

Because Burbank was secretive about his plant breeding methods and iffy with his notetaking the origins of some of his most famous crosses are still mysterious.

THE PLUM DETECTIVE Rachel Spaeth is the garden curator at Luther Burbank Home & Gardens in Santa Rosa. A fourth-year Ph.D. candidate at UC Davis, she is attempting to establish the identity and ancestry of Luther Burbank plum varieties through genetic sequencing. She is holding one of Burbanks fruit prints.

Enter Rachel Spaeth, the garden curator at Luther Burbank Home & Gardens in Santa Rosa and a fourth-year Ph.D. candidate at UC Davis, working in the horticulture and agronomy graduate group.

Spaeth said she is looking at all of the genetic diversity that we can find in Luther Burbank plums, working to unravel their identity and ancestry.

We kind of know what he said they (his hybrid crosses) were, and genetically, I should be able to tell that, she said.

When talking to laymen, Spaeth likes to begin with this clarification: When somebody says the word plum, its a generic term and its kind of a misnomer, because plum actually refers to between 17 and 40 different species of organisms, Spaeth said, depending on which kind of taxonomist youre asking.

Spaeth is looking at 60 living plums within 10 of those species. She is using plant material from living Burbank plum trees to sequence the genomes of Burbanks plum varieties and she ultimately hopes to make use of the roughly century-old DNA in Burbanks fruit prints to confirm these identifications.

Spaeth said her goals are to verify Burbanks claims about his crosses and to establish a genetic collection of characteristics, based on Burbanks discoveries, for plant breeders in the future.

One of the major goals is to just verify his claims, she said, noting that Burbanks breeding claims were often disbelieved. Luther would say that these were the parents of something, but especially with his plum-apricot crosses, people didnt really believe that he crossbred a plum with an apricot until 50 years after his death, when somebody else was able to reproduce a plum-apricot crop.

NOTEWORTHY With only a high school education and no scientific training, Burbank was a self-taught genius and a relentless experimenter, who, it turns out, took extremely poor notes.

Long before genetic engineering was even dreamt of, Burbank took a swashbuckling approach toward plant breeding blithely crossing species boundaries to create fertile hybrids, something youre not supposed to be able to do.

Luther was unique in that he would frequently cross different species, especially ones that people didnt think were possible, Spaeth said. But if he saw that the flower morphology was similar or they had overlapping bloom periods, or if the fruit looked really similar, then he would deduce that, OK, maybe I can cross these and hed just try it sometimes repetitively if he really wanted it to work, and sometimes he would get really good results.

Spaeth said the Santa Rosa plum is probably the prime example of this.

Its a cross between a European plum and the Japanese plum. And in creating that hybridized cross, he created a plum that was partially self-fertile, but then also could be used to pollinize both European and Japanese plums. So the Santa Rosa plum became the universal pollinizer a role she said it still plays today. Even if its not grown commercially for fresh market, theyll always have a couple in the orchard just to make sure that they get a good fruit set on everything else.

The other thing is its really intermediate in bloom time, she said. So whenever youre looking at plant patents for plums, almost all of them will tell you it flowers two weeks before Santa Rosa or two weeks after Santa Rosa. So really its kind of like the gold standard.

Before heading out to the orchards to gather plant material, Spaeth needed to get a comprehensive list of all the plums introduced by Burbank. She used two different source books, W.L. Howards Luther Burbanks Plant Contributions (1945), a near comprehensive guide to everything Burbank introduced, and U.P. Hedricks Plums of New York (1911), a 750-page tome, filled with beautiful watercolor illustrations of plums.

Spaeth hit gold immediately.

When I looked through the Hedrick book, I used an online PDF and searched for the keyword Burbank, and I was able to discover six plums that Howard didnt find, just because of the modern tools that we have available to us. So that was really exciting, she said.

Then using that list as her starting point, she began gathering plant material leaves and fruit from plum trees at three different sites: Luther Burbank Home and Gardens in Santa Rosa (where theres a small orchard with 34 varieties of plums grafted onto five trees); the Burbank Experiment Farm in Sebastopol (where some of the plum trees are so old they were planted by Burbank himself); and the USDAs Wolfskill Experimental Orchards in Winters.

If we find a cultivar thats in all three places when we sequence the genome, it should all be identical, Spaeth said. And then we can say this is exactly that plum. Then that becomes the voucher.

To make a definitive identification, You have to corroborate material from three different sources, she said. Two different sources is OK; three is better. So if we have a sample from all three, and it comes back that one of them is different, then we have to do a little bit more legwork with phenotyping: so it would be like really looking at fruit quality, flowering time and all of that information to try to match it to the historic data that we have.

BURBANK The Burbank plum was produced from a plum pit sent to Burbank by a Japanese agent in 1883. It was named in honor of Burbank, who introduced it to the United States.

Fruit prints then and now

Ultimately, she would like to do genetic testing on Burbanks original fruit prints, which will require scraping some of the dried fruit matter off. Some of Burbanks fruit prints are located at Luther Burbank Home & Gardens, but many more are located in the Library of Congress.

To figure out the smallest amount of materials she can take to get a good sample, Spaeth has been making her own fruit prints and practicing on those.

The goal is to use my prints to see how little material possible you need to be able to get DNA. Were using techniques that people would use in forensic archaeology, adding different compounds or increasing the amount of time that your reaction has to take place so that you can get good data out of it, said Spaeth, who sometimes jokes that she feels like the Indiana Jones of the plant world.

When shes confident in her sampling method, shell request permission to take samples from Burbanks fruit prints in the Library of Congress.

Creating a genetic list of ingredients, a l Burbank

The ultimate goal of Spaeths genetic research is to pinpoint which sections of a plums genetic code create certain characteristics. This is done through quantitative trait locus (QTL) analysis, which is a statistical method that links phenotypic data (measurements of traits such as color, shape, disease resistance, etc.) with genotypic data in order to explain the genetic basis of a specific trait.

The cool thing about Luthers plums is that they have a huge range of not only genetic diversity, but phenotypic diversity. So youre looking at every color under the rainbow of plums, every size, every shape, whether its free stone or cling stone, Spaeth said.

All of those characteristics get scored. And then we compare all of those characteristics to the genome, she said. Youre looking for QTL markers.

In other words, youre looking for the recipe that makes the pointy bottom plum versus the recipe that makes a smooth bottom. And then once you know that recipe, people can use that information in future breeding experiments.

According to Spaeth, the ability to create such a recipe really emphasizes the importance of historic collections, such as those at Luther Burbank Home & Gardens and the Luther Burbank Experiment Farm.

Because we wouldnt have this resource, if we didnt have people that were curating and cataloging these sorts of things, she said.

Bringing the past into the future

Knowing the recipe for a phenotypic trait allows researchers to target specific regions of the genome for genetic engineering as well as traditional breeding.

From a genetic engineering perspective, knowing the recipe for the gene you want allows you to target and edit specific sequences, Spaeth said. This is highly useful if you want to do something like move a disease-resistance gene from cherry into plum without having to shuffle and sort the two genomes through traditional methods.

What would Burbank think of modern genetic engineering?

"It is unfair to impart our 21st century mindset on someone who lived most of his life without electricity or cars, Spaeth said. However, if I had to venture a guess, I would say that Luther would be open to using all of the tools in the kit to further advance his breeding lines.

By cracking the genetic code of Burbanks hybrids and by creating a genetic database of their component parts, Spaeth is giving Luther Burbank a new place in the modern world so that future generations of scientists and plant lovers can benefit once more from his prodigious creativity.

View post:
Unraveling the mystery of Luther Burbank's famous plums - Sonoma West

Read More...

How misguided regulation has kept a GMO ‘superfood’ off the market: Q&A with Golden Rice author Ed Regis – Genetic Literacy Project

November 11th, 2019 11:44 am

For us in the West, the ferocious debate over genetic engineering isnt a matter of life and death. We argue about the safety of Impossible Burgers and the potential risks associated with new breeding techniques like CRISPR gene editing, but nobody will go hungry or die of malnutrition pending the outcome of these arguments. Sadly, the same isnt true in the developing world.

The tragic tale of global vitamin A deficiency (VAD) and the life-saving (but still unavailable) solution known as Golden Rice has been told millions of times, 246 million according to Google. But to briefly recap: roughly 250 million people, mostly preschool children in southeast Asia, are vitamin A deficient. Between 250,000 and 500,000 of them go blind every yearand half die within 12 months of losing their sight. Genetically engineered Golden Rice, fortified with the vitamin A precursor beta carotene, could alleviate much of this suffering without otherwise harming human health or the environment, according to a mountain of studies.

So why are so many people still dying of a preventable condition?

Thats the rather frustrating part of the story science writer Ed Regis examines in his new book Golden Rice: The Imperiled Birth of a GMO Superfood. In just over 200 pages, Regis gives a crash course on genetic engineering and explains the messy history of Golden Rice, disabusing the reader of many popular myths along the way. Environmental activist group Greenpeace, for example, is often identified in the press as the primary obstacle to releasing Golden Rice. Despite all its lobbying, however, the NGO has had a relatively minor impact on the crops development.

Instead of pointing the finger at Greenpeace, Regis says the blame lies mostly with overly cautious governments, many of which regulate GMOs as if they were biological weapons. Hoping to avoid the unintended (and so far undiscovered) consequences of growing genetically engineered crops, regulators unintentionally rob people of their eyesight and often their lives.

In a Q&A session with Genetic Literacy Project editor Cameron English, Regis offers a birds eye view of the ongoing controversy and highlights some lesser-known but still significant aspects of the Golden Rice story.

Cameron English: Golden Rice seems simple conceptually. As you point out, scientists just had to direct the plants existing biochemical machinery to synthesize beta carotene in the rice grain, as it does in the rest of the plant. Why did this prove so challenging to achieve in the lab?

For one thing, it had never been done beforerewriting a plants genes to make it express a trait that it normally did not have. Nobody was sure that it was even possible. There were different ways of accomplishing that goal, and there were a lot of technical difficulties in doing the actual hands-on lab work, and getting everything lined up correctly at the genetic level so that beta carotene would appear in the rice grain. There were incredible numbers of false starts, dead ends, and unforeseen technical problems to overcome, and it took years of trial and error for the inventors to get it all working properly. It was just a hard problem, both scientifically, in theory, and technologically, in practice.

CE: You write that Golden Rice could make VAD a thing of the past in developing Asian countries. Why is this biotech crop a better solution than alternative proposals, like distributing vitamin supplements?

Supplement programs have been tried, and of course they do some good, but the problem is that such programs require a substantial and permanent infrastructure. They require a supply chain, personnel to distribute the stuff, record keeping, and the like, plus sufficient and continuous funding to keep it all going across time. Also, there is no way to guarantee that supplements will reach every last person who needs them.

Golden Rice, by contrast, requires none of that. The seeds will be given at no cost to small landowner farmers, and the rice will be no more expensive to consumers than plain and ordinary white rice. Plus, theres the principle that Plants reproduce, pills dont. Once Golden Rice is introduced, its a system that just goes of itself. The product replaces what people already eat on a daily basis with something that could save their sight and lives in the process.

CE: Tell us the story about night blindness you recount from Catherine Prices book. Does that anecdote underscore the problem that Golden Rice could solve?

We in the rich, developed Western countries know practically nothing about [VAD]. We have virtually no experience of it because we get the micronutrients we need from ordinary foods and vitamin supplements. One of the first symptoms of vitamin A deficiency is night blindness, which means pretty much what it says. But to convey this as an actual, lived experience I quote from Catherine Prices excellent book, Vitamania, in which she describes what happens to vitamin A deficient children in poor, developing countries.

While they lead an active life during the day, they gradually withdraw and stop playing as twilight approaches. With the fall of night, they basically just sit in place and wait for help, because they have lost their sight in darkness, and their life grinds to a halt. In countries such as the Philippines, where people eat rice as a staple, at every meal, Golden Rice could prevent this from happening, and even reverse the symptoms in children already affected by VAD.

CE: You point out that Greenpeace struggled with a moral dilemma before forcefully coming out against Golden Rice. Tells about that situation.

In 2001, the year after the Golden Rice protype was announced in Science, a Greenpeace official by the name of Benedikt Haerlin visited Ingo Potrykus, the co-inventor, at his home in Switzerland. Haerlin discussed whether or not to make the provitamin A rice an exception to Greenpeaces otherwise absolute and rigid opposition to any and all genetically engineered foods. He had initially acknowledged that there was a moral difference between GMOs that were merely agriculturally superiorin being pesticide- or herbicide-resistant, for exampleand a GMO that was so nutritionally beneficial that it actually had the potential to save peoples lives and sight.

But apparently that distinction made no difference because in the end both Haerlin himself and Greenpeace as an organization soon took the view that Golden Rice had to be opposed, even stopped, no matter what its possible health benefits might be.

CE: Greenpeace also claimed that poverty and insufficiently diverse diet were the root causes of vitamin A deficiency. Therefore, they said, developing biofortified crops was misguided. That sounds like a reasonable argument, so whats wrong with Greenpeaces analysis here?

This is like arguing that until we find a cure for cancer we should not treat patients by means of surgery, chemotherapy or radiation therapy. This is totally illogical on the face of it. And the same is true of the argument that since poverty is the cause of the problem that therefore the only solution is to eradicate it. Everyones in favor of eradicating poverty, but there are things we can do in the interim while advancing that far-off and utopian goal, which arguably will take some time to accomplish. Biofortified Golden Rice, along with supplementation and a more diverse diet, can help prevent vitamin A deficiency. If a solution, or a set of solutions, is available, lets implement them while also striving to reduce poverty. Both can be done together, you dont have to choose between one and the other.

CE: Many people believe that Greenpeace and other anti-GMO groups are the main roadblock to getting Golden Rice into the hands of farmers. But you write that the activists dont deserve that much credit. What else has kept Golden Rice off the market?

Greenpeaces long history of anti-GMO rhetoric, diatribes, street demonstrations, protests, dressing up in monster crop costumes, and all the rest of it actually did nothing to halt research and development of Golden Rice. There are two reasons why it took 20 years to bring Golden Rice to the point where it won approval for release in four countries: Australia, New Zealand, the United States and Canada. The first is that it takes a long time to breed increasingly higher concentrations of beta carotene (or any other valuable trait) into new strains of rice (or any other plant). Plant breeding is not like a chemistry experiment that you can repeat immediately as many times as you want. Rather, plant growth is an inherently slow and glacial process that cant be [sped] up meaningfully except under certain special laboratory conditions that are expensive and hard to foster and sustain.

The second reason is the retarding force of government regulations on GMO crop development. Those regulations, which cover plant breeding, experimentation, and field trials, among other things, are so oppressively burdensome and costly that they make compliance inordinately time-consuming and expensive.

CE: Whats the Cartagena Protocol and how has it affected the development of Golden Rice?

The Cartagena Protocol was an international agreement, sponsored and developed by the United Nations, which aimed to ensure the safe handling, transport and use of living modified organisms (LMOs) resulting from modern biotechnology that may have adverse effects on biological diversity, taking into account also risks to human health.

On the face of it, this precautionary approach is plausible, even innocuous. In actual practice, the protocol amounts to a sweeping set of guidelines, requirements, and procedures pertaining to GMOs that were legally binding on the nations that were parties to the agreement, coupled with a set of mechanisms to enforce and ensure compliance. These oppressive and stifling rules and regulations soon turned into a nightmare for GMO developers, and did more than anything else to slow down the progress of Golden Rice.

Ingo Potrykus, the co-inventor of Golden Rice, has estimated that adherence to government regulations on GMOs resulting from the Cartagena Protocol and the precautionary principle, caused a delay of up to ten years in the development of the final product. That is a tragedy, caused by the very governments that are supposed to protect our health, but in this case did the opposite.

CE: Once a prototype of Golden Rice was developed, the prestigious science journal Nature refused to publish the study documenting the successful experiment. Why do you think Nature reacted that way, and what does it tell us about the cultural climate during the period when Golden Rice was first developed?

Well, I cant speak for the Nature editors, so in this case youre asking the wrong person. In my book, I quote what Ingo Potrykus had to say about the matter, which was:

The Nature editor did not even consider it worth showing the manuscript to a referee, and sent it back immediately. Even supportive letters from famous European scientists did not help. From other publications in Nature at that time we got the impression that Nature was more interested in cases which would rather question instead of support the value of genetic engineering technology.

And I will leave it at that.

CE: The classic objection to GMOs, including Golden Rice, is that theyre unnatural. Would you summarize your response to that claim in the book?

In the book I show that in fact most of the foods that we eat are unnatural in the sense that they are products of years of artificial selection, often using techniques other than conventional crossbreeding.

In particular I cite the example of Rio Red grapefruit, which is sold all over America and is not considered a GMO, despite the fact that its genes have been scrambled over the years by artificial means including radiation mutation breeding, in the form of thermal neutron (thN) bombardment, which was done at the Brookhaven National Laboratory. This highly mutant and genetically modified grapefruit variety is on file at the Joint FAO/IAEA Mutant Variety Database, at the headquarters of the International Atomic Energy Agency (IAEA), in Vienna, Austria. You can hardly get more unnatural than Rio Red grapefruit.

By contrast, there is a plant whose roots in the ground are potatoes, but whose above ground fruit are tomatoes. This is the so-called TomTato, and was created by exclusively conventional means, i.e., grafting, which goes back thousands of years. But which of the two is more unnaturalthe Rio Red grapefruit or the freakish TomTato? And why does it matter?

CE: There are a lot of transgenic crops being developed, so why did Golden Rice become such a lightening rod for controversy in the GMO debate?

Because if it gets approved, works, and ends up saving lives and sight, it will lead to greater acceptance of GMO foods in general, which is the very last thing that GMO opponents want. That cannot be said of any other GMO.

CE: Bangladesh appears poised to release Golden Rice before the end of 2019. Are you hopeful that farmers will soon have access to it, or do you foresee more political and regulatory obstacles getting in the way?

In the words of Jack Reacher (the hero of Lee Childs crime novels), Hope for the best, prepare for the worst. Seeing what has happened to Golden Rice over the course of 20 years, nothing would surprise me going forward. I would sort of be more surprised if Bangladesh approved it and it was grown and people ate it than if it were banned outright in the countries where its needed most. That is the most infuriating part of the whole story.

Ed Regisis a science writer whose work has appeared inScientific American,Harpers,Wired,Nature,Discover, and theNew York Times,among other publications. He is the author of ten books, includingWhat Is Life? Investigating the Nature of Life in the Age of Synthetic Biology.

Cameron J. English is the GLPs senior agricultural genetics and special projects editor. He co-hosts the Biotech Facts and Fallacies podcast. Follow him on Twitter @camjenglish

More here:
How misguided regulation has kept a GMO 'superfood' off the market: Q&A with Golden Rice author Ed Regis - Genetic Literacy Project

Read More...

A Brave New World: Tech Ethics Course Encourages Students to Mull the Implications of New Technologies – Harbus Online

November 11th, 2019 11:44 am

Ryo Takahashi, CEO

Ryo Takahashi (MBA 20) speaks with Professor Michael Sandel.

Bracing for a Brave New World

Scenes of genetic selection in Gattaca (1997), the telescreen surveillance state depicted in Orwells 1984 (1948), and the apprehension of criminals before they commit a crime as depicted in Minority Report (2002) may seem like distant dystopian science fiction.

Until recently. The rate of progress in technology has surpassed not only our ability to regulate its uses, but also our ability to engage in meaningful discourse on how technology ought to be used.

Recent advances in human trials for gene-editing technologies such as CRISPR, the deployment of emotion recognition in surveillance systems, and innovations in predictive policing technology all suggest that we are getting progressively closer to the use of such technologies, once the work of dystopian fiction, without adequately thinking through the potential consequences.

Growing interest over the promises and perils of technology has led to Professors Douglas Melton and Michael Sandel to offer Tech Ethics, a university-wide course being taught this year at HBSs Klarman Hall.

This is a new version of a course that Doug Melton and I have taught on and off over the past 10 years or so, said Professor Sandel.

The course was originally called Ethics and Biotechnology. The original focus of the course was on the ethics of stem cell research, genetic engineering, and the ethical implications of the genetic and biotech revolution.

Since then, the course has evolved and we have added topics related to AI, robots, algorithms, and big data, given the growing importance of those areas.

When we were debating questions of stem cell research and parents genetically creating designer babies, these were fascinating but somewhat distant from students personal experience. But when we talk about the ethics of the internet, or of the behaviors of technology companies, these are very immediate questions, because these are technologies that students interact with every hour of every day. This has heightened interest in the course.

Inviting debate on ethical issues

To date, the course has focused on topics as far-ranging as gene editing and genetic enhancement, algorithmic fairness and discrimination, the role of big data and social media, and genetically altered athletes and animals. Issues such as fairness, paternalism, freedom, and agency of the individual have oftentimes been at the core of many debates.

Sandel urges students who enroll in the course to come ready to think through and explore issues, as opposed to coming in with fixed opinions.

As democratic citizens, we have to be asking these questions today. If we dont think through the ethical implications of new technologies, we will be at their mercy. Technology is a tool. But its something we can use responsibly only if we reflect on how the tools should be used.

How can the tools be made to advance the common good, rather than to acquire a momentum of their own that winds up undermining democratic elections, or transforming the relations of parents to children, or leading to global warming if we dont think through our relation to nature? asks Sandel.

A course for all students

Each week, the course draws students from Harvards various schools, ranging from undergraduates to students pursuing professional degrees, including from Harvard Business School and Harvard Law School.

When I saw the course, I knew immediately that I want to take it, said Alex Mao (MBA 20).

I enrolled in Tech Ethics because I want to hear what other people think. On some issues I have a firm opinion whereas on others Im eager to hear others perspectives. We need to think about the implications of these technologies since its moving so quickly.

Previous versions of the course were for undergraduates, said Sandel.

Over time, it became clear to us that tech ethics is a subject that has become central to the various professionsof business, law, medicine, public health, government and public policy, the divinity school, etc.

Thats why we decided to make the course open to all students across the university, he said.

Klarman Hall seemed like the perfect venue for such an endeavor.

In a conversation with President Bacow about our ambition to launch a university-wide course, he strongly encouraged us to do it across the river, in this gorgeous new auditorium at HBS. He felt it would symbolize the idea of drawing together students from across the University into a shared, One Harvard academic community.

I was unsure whether undergrads would travel across the river for a course. We didnt know until the first day of class, when more than 1,000 students packed Klarman Hall, he said.

Given whats at stake, the long march may well be worth it.

Ryo Takahashi (MBA 20), originally from Japan, is a management consultant and writer. Prior to Harvard Business School, he worked as a Project Manager at the World Economic Forum (WEF) and was a Senior Associate at McKinsey & Company. Prior to these roles he worked at the Economist and the Japan Times. His writing has appeared in Time magazine, the Economist, the Japan Times, and the World Economic Forum, among other outlets. He received his B.A. in Economics (with Distinction) from The University of Tokyo and was also a Rotary Scholar to the London School of Economics.

Follow this link:
A Brave New World: Tech Ethics Course Encourages Students to Mull the Implications of New Technologies - Harbus Online

Read More...

Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World’s First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic…

November 11th, 2019 11:42 am

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, published updated clinical data from the ongoing phase 2a study (HEP101) of its lead product candidate HepaStem in patients with Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF. The data were presented in an oral presentation at the Annual Meeting of the American Association for Study of Liver Diseases (AASLD) on November 10, 2019, in Boston, by Prometheras principal investigator Prof. F. Nevens, KULeuven, Belgium. The data set confirmed earlier findings presented at The International Liver Congress - ILC 2019 in April.

Currently, liver transplant is the only rescue treatment for patients suffering from ACLF and to a lesser degree for patients with acute decompensation of the liver (AD). There are no other existing therapies that can rescue the end-stage-liver failure. Promethera is developing HepaStem as an alternative to transplant; it consists of liver derived stem cells that are obtained from ethically donated healthy human organs and expanded in GMP culture conditions. These liver derived signaling stem cells migrate through the blood stream to reach the liver, where they support the tissue regeneration via their potent secretome.

In the trial HEP101, HepaStem has been intravenously infused in single or repeated injections in multiple ascending doses in patients to assess the tolerability and the safety profile of the treatment. The trial which recruited a total of 24 patients, including 16 patients with ACLF and 8 patients with AD has met its primary endpoint.

With one or two repeated doses up to 1.2 million cells per kilogram of body weight, no adverse events related to HepaStem occurred and no clinically significant changes were shown in platelet count, fibrinogen levels, and coagulation factors following HepaStem infusion. The demonstrated safety of two infusions of 1.2 million cells per kilogram of body weight provide solid guidance for conducting the subsequent trials. In addition to the positive safety profile, the study has shown trends in efficacy with improvement in three indicators of liver disease severity; Model for End Stage Liver Disease score (MELD), Child-Pugh score and bilirubin levels, 28 days and three months after treatment initiation. Promethera plans to demonstrate the efficacy of HepaStem at 1.0 million cells per kilogram of body weight in ACLF with a large multicentric double blind placebo-controlled trial (HEP102). The study HEP102 is expected to start end 2019.

We continue to pioneer the use of liver stem cells for the treatment of severe liver diseases and the updated status from the worlds first clinical trial evaluating a cell-based therapy in ACLF gives us confidence about the safety aspects and the broad therapeutic potential of our therapy, said Etienne Sokal, M.D., Ph.D., Prometheras Group Chief Medical Officer. As a potential first tangible alternative to organ transplantation for an ever-growing patient population, HepaStem will advance into a larger efficacy trial in ACLF focusing on a reduced need for transplantation and a decreased mortality.

Prof. Nevens added, With the data set having evolved since we last presented results at this years ILC Congress, the Phase 2a trial provides a strong rationale for further clinical evaluation of the therapeutic concept and has provided a safe dosing regimen which will guide future studies.

About Promethera Biosciences

Promethera Biosciences is a global innovator in liver therapeutics whose mission is to bring life-saving treatments to reduce the need for liver transplantation. Our lead clinical program, derived from our patented cell technology platform HepaStem, is designed to benefit from its immune-modulatory and anti-fibrotic properties. In addition to our cell-based pipeline we develop antibody technologies, such as the antiTNF-R1 antibody Atrosimab, to complement and diversify our therapeutic options. We are a team of international experts operating out of facilities in Mont-Saint-Guibert, Belgium, Durham, NC, USA, Tokyo, Japan and Basel, Switzerland.

Promethera, HepaStem, H2stem, are all registered trademarks of the PROMETHERA group.

Originally posted here:
Promethera Biosciences Presents Updated Clinical Results at AASLD 2019 for World's First Stem Cell Therapy Trial using HepaStem in Acute-on-Chronic...

Read More...

Global Stem Cell Therapy Market 2019 : Analysis and Market Expert Research Report Forecast to 2024 – Eastlake Times

November 11th, 2019 11:42 am

GlobalStem Cell TherapyMarket Overview:

We,MRInsights.biz, after comprehensive analysis, have introduced a new research study onGlobalStem Cell TherapyMarket. The report provides a unique, first-time market and competitive analysis of the size, segmentation, competition, trends, and outlook in the manufacturers operating in theStem Cell Therapymarket. The report comprises all analytical and statistical brief summary regarding market summary, growth, demand, and forecast analysis. It covers the key manufacturers profiles in detail along with market entry strategies, production analysis, market share, revenue forecast and regional analysis of the market. It particularly delivers delivering wide-ranging analytical information on regional segmentation.

The researchers team presents the analytical data and figures in the report in an effectual way with the help of graphs, diagrams, pie charts, and other pictorial illustrations. The report focuses on providing the clients and other readers with all the necessary information regardingStem Cell Therapymarket share, new product launch, applications, provinces, businesses, economic growth, and supply and demand rate.It examines the industry potentials for each geographical region with respect to the customer purchasing patterns, macroeconomic parameters, market demand and supply states, and growth rate.

DOWNLOAD FREE SAMPLE REPORT:https://www.mrinsights.biz/report-detail/179414/request-sample

Leading vendors covered in the report are:Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Growth Drivers And Industry Trends:

TheStem Cell Therapymarket is divided into different segments with reference to the geographic, types, applications, and manufacturers. Our team of researchers has followed a focused and realistic research outline in order to investigate the important market dynamics like drivers, restraints, and opportunities in many regions across the world.

Geographical Analysis:

The study details country-level aspects based on each segment and gives estimates in terms of market size. The key regional trends beneficial to the growth of theStem Cell Therapymarket are discussed. Further, it analyzes the market potential for every nation. Geographic segmentation covered in the market report:

ACCESS FULL REPORT:https://www.mrinsights.biz/report/global-stem-cell-therapy-market-growth-status-and-179414.html

What The GlobalStem Cell TherapyMarket Report Contains:

Research objectives

TheStem Cell Therapymarket size is calculable in terms of revenue (US$) and production volume during this report. Moreover, the study showcases back-to-back parameters like application, improvement, product growth, and diverse structures & key processes. The report delivers a perfect solution, which incorporates current market intelligence, future projections for the growth, technology inputs, and future market trends. Then it serves a market outlook for 20142024 and sets the forecast.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@mrinsights.biz), who will ensure that you get a report that suits your needs.Stem Cell Therapy

Go here to read the rest:
Global Stem Cell Therapy Market 2019 : Analysis and Market Expert Research Report Forecast to 2024 - Eastlake Times

Read More...

Stem Cell Therapy Market to Grow at 11.0% CAGR to 2021 – Weekly Spy

November 11th, 2019 11:42 am

The Global report titled on Stem Cell Therapy Market delivering key insights and providing a competitive advantage to clients through a detailed report. The report also details the information about the global market status, growth rate, future trends, market drivers, challenges, opportunities and porters forces analysis with respect to these elements. An exclusive data offered in this report is collected by research and industry experts team.

Get Free Sample Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=281584

The Global Stem Cell Therapy Market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach US$ 145.8 Million by 2021. This report spread across 120 Pages, Profiling 10 Companies and Supported with 60 Tables and 37 figures is now available in this research.

Top Companies profiled in the Stem Cell Therapy Market:

Growth in the global stem cell therapy market is driven by factors such as the growing awareness of the therapeutic potency of stem cells in effective disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for development of stem cell therapies, identification of new stem cell lines, and developments in infrastructure related to stem cell banking and processing. In addition, countries such as Japan, South Korea, and China are offering new growth opportunities for players operating in this market.

Premium Insights:

1 Stem Cell Therapy Market Overview

2 Regional Analysis: Market, By Type, 2016 vs 2021 (USD Million)

3 Global Market, By Therapeutic Application, 20162021 (USD Million)

4 Regional Analysis: Market, By Cell Source, 2016 vs 2021 (USD Million)

Check Discount Offers @ https://www.reportsnreports.com/contacts/discount.aspx?name=281584

Based on the type of therapy, the allogeneic stem cell therapy segment is estimated to command the larger share of the global stem cell therapy market in 2016. This growth can be attributed to the growing availability of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easier production scale-up due to easy availability of sources of stem cells, and growing number of clinical trials of allogeneic stem cell therapies as compared to autologous stem cell therapies.

Competitive Landscape of Stem Cell Therapy Market:

1 Overview

2 Market Ranking

3 Strategic Benchmarking

3.1 Product Development and Commercialization

4 Competitive Scenario

5 Recent Developments

5.1 Product Launches and Approvals

5.2 Expansions

5.3 Agreements, Collaborations, and Partnerships

Ask Question @ https://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=281584

Reason to access this report:

From an insight perspective, this research report focuses on various levels of analysismarket share analysis of the top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the stem cell therapy market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

Original post:
Stem Cell Therapy Market to Grow at 11.0% CAGR to 2021 - Weekly Spy

Read More...

Stem Cell Therapy Market-Global and Regional Analysis by Top Key Industry Players, Key Regions, Product Segments, and Applications 2025 – ZMR News…

November 11th, 2019 11:42 am

A leading research firm, Zion Market Research added a latest industry report on "Global Stem Cell Therapy Market" consisting of 110+ pages during the forecast period and Stem Cell Therapy Market report offers a comprehensive research updates and information related to market growth, demand, opportunities in the global Stem Cell Therapy Market.

According to the report the Stem Cell Therapy Market-Global and Regional Analysis by Top Key Industry Players, Key Regions, Product Segments, and Applications 2025

The Stem Cell Therapy Market report provides in-depth analysis and insights into developments impacting businesses and enterprises on global and regional level. The report covers the global Stem Cell Therapy Market performance in terms of revenue contribution from various segments and includes a detailed analysis of key trends, drivers, restraints, and opportunities influencing revenue growth of the global consumer electronics market.This report studies the global Stem Cell Therapy Market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the global Stem Cell Therapy Market by companies, region, type and end-use industry.

Request a Free Sample Report on Stem Cell Therapy Market: https://www.zionmarketresearch.com/sample/stem-cell-therapy-market

The Stem Cell Therapy Market report mainly includes the major company profiles with their annual sales & revenue, business strategies, company major products, profits, industry growth parameters, industry contribution on global and regional level.This report covers the global Stem Cell Therapy Market performance in terms of value and volume contribution. This section also includes major company analysis of key trends, drivers, restraints, challenges, and opportunities, which are influencing the global Stem Cell Therapy Market. Impact analysis of key growth drivers and restraints, based on the weighted average model, is included in this report to better equip clients with crystal clear decision-making insights.

The Stem Cell Therapy Market research report mainly segmented into types, applications and regions.The market overview section highlights the Stem Cell Therapy Market definition, taxonomy, and an overview of the parent market across the globe and region wise.To provide better understanding of the global Stem Cell Therapy Market, the report includes in-depth analysis of drivers, restraints, and trends in all major regions namely, Asia Pacific, North America, Europe, Latin America and the Middle East & Africa, which influence the current market scenario and future status of the global Stem Cell Therapy Market over the forecast period.

Get Free PDF Brochure of this Report: https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

The Stem Cell Therapy Market report provides company market size, share analysis in order to give a broader overview of the key players in the market. Additionally, the report also includes key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, product and regional expansion of major participants involved in the market on the global and regional basis.

Major Company Profiles Covered in This Report:

Anterogen Co., Ltd., RTI SurgicalInc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasiveInc., and AlloSource.

Some of the major objectives of this report:

1) To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Stem Cell Therapy Market.

2. To provide insights about factors affecting the market growth. To analyze the Stem Cell Therapy Market based on various factors- price analysis, supply chain analysis, porter five force analysis etc.

3. To provide historical and forecast revenue of the Stem Cell Therapy Market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and Rest of the World.

4. Country level analysis of the market with respect to the current market size and future prospective.

5. To provide country level analysis of the market for segment by application, product type and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Stem Cell Therapy Market.

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the clients needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to usafter allif you do well, a little of the light shines on us.

Contact Us:

Zion Market Research

244 Fifth Avenue, Suite N202

New York, 10001, United States

Tel: +49-322 210 92714

USA/Canada Toll Free No.1-855-465-4651

Email: sales@zionmarketresearch.com

Website: https://www.zionmarketresearch.com

As one of the lead news writers at zmr news reports, Hirens specialization lies in the science, technology, Health & business domains. His passion for the latest developments in cloud technology, connected devices, nanotechnology, and virtual reality, among others, shines through in the most recent industry coverage he provides. Hirens take on the impact of digital technologies across the technology, health and business domains gives his writing a fresh and modern outlook.

See the rest here:
Stem Cell Therapy Market-Global and Regional Analysis by Top Key Industry Players, Key Regions, Product Segments, and Applications 2025 - ZMR News...

Read More...

Waiting For The Sign that Protections Are Needed For Genetic Data? Here It Is. – Forbes

November 11th, 2019 11:41 am

I just attended theNational Society of Genetic Counselors Annual Meetingin Salt Lake City, UT where I met some of the brightest minds in genetics, heard about mind-bending new technologies, and was reminded of the many ways that genetic counseling and testing is improving health, transforming lives, and driving precision medicine forward.

With that bright promise freshly in mind, several recent stories have cast a stark reminder of the ways genetic testing can, andis,being used nefariously.I published an article on this topicjust a few short weeks ago and didnt foresee that it would need a part II so soon. Consider the following:

The Trump administration already announced that they would require DNA samples from asylum-seekers at the Mexican border for rapid DNA testing to confirm family relationships.In a move called transparently xenophobic in its intention, the Trump Administration now plans to collect DNA from individuals in federal immigration custody and add those samples to the national FBI crime database.

MIAMI : A judges gavel rests on top of a desk (Photo by Joe Raedle/Getty Images)

A Judge in the Floridas Ninth Judicial Circuit Court signed a warrant allowing a detective to successfully obtain a warrant to search GEDMatchs genetic database,even for users who opted out of appearing in police search results.This decision brings into question whether larger databases, like those of 23andMe and Ancestry, are subject to the same sort of warrants, despite their privacy policies.23andMe does not believe that this decision impacts them, but that remains to be seen.However, it is possible that any privacy policyis only as strong as a police departments ability to get a willing judge to sign a search warrant.

NEW YORK, NY - JUNE 20: (Photo by Santiago Felipe/Getty Images)

A recent genetic study on homosexualityraised eyebrows for many reasons, including that it appeared that homosexuality was being positioned as a condition or worse yet a disease to study and understand.An informativeDNA Exchange blogpost by certified genetic counselor Austin McKittrickeloquently outlined the issues, including that the study utilized data from the UK Biobank and 23andMe.Consumers consenting to 23andMe research studies may falsely believe that their data are being used only to further critical health care problems, like finding a treatment for Parkinsons disease, rather than for research that could potentially lead to discrimination or stigmatization of groups of people.Within days of this research being published an app called GenePlaza was developedthat, for about $5, could tell you how gay you are.Can you imagine this app being used at a middle school slumber party, with results posted to social media?But worse yet, the apps developer is based in Uganda,a country that announced plans that it would make homosexuality punishable by the death penalty.

Now, for just a moment, think about these three developments in unison.Our government is requiring DNA collection for immigrants in custody and those samples will enter our federal crime databases.Large databases, even for consumer entertainment, are subject to search warrant.Genetic data are being collected and used to make associations (accurate, or not) to a trait that may be punishable by death in some countries.

If we have been waiting for a sign thatwe need federal, or international, protections for genetic data and how it can be used, we now have that sign.

Read the original here:
Waiting For The Sign that Protections Are Needed For Genetic Data? Here It Is. - Forbes

Read More...

Your hatred of heart-healthy veggies could be genetic – fox5sandiego.com

November 11th, 2019 11:41 am

CONNECTICUT If certain vegetables have always made you gag, you may be more than a picky eater. Instead, you might be what scientists call a super-taster: a person with a genetic predisposition to taste food differently.

Unfortunately, being a super-taster doesnt make everything taste better. In fact, it can do the opposite.

Super-tasters are extremely sensitive to bitterness, a common characteristic of many dark green, leafy veggies such as broccoli, cauliflower, cabbage and Brussels sprouts, to name a few.

The person who has that genetic propensity gets more of the sulfur flavor of, say, Brussels sprouts, especially if theyve been overcooked, said University of Connecticut professor Valerie Duffy, an expert in the study of food taste, preference and consumption.

So that [bitter] vegetable is disliked, and because people generalize, soon all vegetables are disliked, Duffy said. If you ask people, Do you like vegetables? They dont usually say, Oh yeah, I dont like this, but I like these others. People tend to either like vegetables or not.

In fact, people with the bitter gene are2.6 times more likely to eat fewer vegetables than people who donot have that gene, according to a new study presented Monday at the annual meeting of the American Heart Association.

We wanted to know if genetics affected the ability of people who need to eat heart-healthy foods from eating them, said study author Jennifer Smith, a registered nurse who is a postdoc in cardiovascular science at the University of Kentucky School of Medicine.

While we didnt see results in gene type for sodium, sugar or saturated fat, we did see a difference in vegetables, Smith said, adding that people with the gene tasted a ruin-your-day level of bitterness.

Our sense of taste relies on much more than a gene or two. Receptors on our taste buds are primed to respond to five basic flavors: salty, sweet, sour, bitter and umami, which is a savory flavor created by an amino acid called glutamate (think of mushrooms, soy sauce, broth and aged cheeses).

But its also smelling through the mouth and the touch, texture and temperature of the food, Duffy said. Its very difficult to separate out taste from the rest. So when any of us say the food tastes good, its a composite sensation that were reacting to.

Even our saliva can enter the mix, creating unique ways to experience food.

When we come to the table, we dont perceive the food flavor or the taste of food equally, Duffy said. Some people live in a pastel food world versus others who might live in a more vibrant, neon food world. It could explain some of the differences in our food preference.

While there are more than 25 different taste receptors in our mouth, one, in particular, has been highly researched: the TAS2R38, which has two variants called AVI and PAV.

About 50% of us inherit one of each, and while we can taste bitter and sweet, we are not especially sensitive to bitter foods.

Another 25% of us are called non-tasters because we received two copies of AVI. Non-tasters arent at all sensitive to bitterness; in fact food might actually be perceived as a bit sweeter.

The last 25% of us have two copies of PAV, which creates the extreme sensitivity to the bitterness some plants develop to keep animals from eating them.

When it comes to bitterness in the veggie family, the worst offenders tend to be cruciferous vegetables, such as broccoli, kale, bok choy, arugula, watercress, collards and cauliflower.

Thats too bad, because they are also full of fiber, low in calories and are nutrient powerhouses. Theyre packed with vitamins A and C and something called phytonutrients, which are compounds that may help to lower inflammation.

Rejecting cruciferous or any type of vegetable is a problem for the growing waistline and health of America.

As we age as a population, vegetables are very important for helping us maintain our weight, providing all those wonderful nutrients to help us maintain our immune system and lower inflammation to prevent cancer, heart disease and more, Duffy said.

Food scientists are trying to develop ways to reduce the bitterness in veggies, in the hopes we can keep another generation of super-tasters from rejecting vegetables.

Theres been some success. In fact, the Brussels sprouts we eat today are much sweeter than those our parents or grandparents ate. Dutch growers in the 90s searched their seed archives for older, less bitter varieties, then cross-pollinated them with todays higher-yielding varieties.

People who already reject vegetables might try to use various cooking methods that can mask the bitter taste.

Just because somebody carries the two copies of the bitter gene doesnt mean that they cant enjoy vegetables, Duffy said. Cooking techniques such as adding a little fat, a little bit of sweetness, strong flavors like garlic or roasting them in the oven, which brings out natural sweetness, can all enhance the overall flavor or taste of the vegetable and block the bitterness.

More:
Your hatred of heart-healthy veggies could be genetic - fox5sandiego.com

Read More...

Sequencing the genome of every UK baby would be an ethical minefield – New Scientist News

November 11th, 2019 11:41 am

By Clare Wilson

Tetra Images/Getty Images

Plans for the National Health Service to sequence the DNA of every baby born in the UK, starting with a pilot scheme of 20,000 children, were announced by health minister Matt Hancock this week. It sounds like the UK is leading the way in high-tech healthcare but doctors are saying the idea is ethically questionable.

Babies are already tested for certain health conditions soon after birth, so it may seem as though sequencing their genome, their entire set of genes, is a simple upgrade of this routine screening, but that isnt the case.

UK babies are tested for nine carefully selected conditions, all of which can be avoided or lessened with pre-emptive treatment. For instance, the metabolic disorder phenylketonuria can cause brain damage, but this can be avoided through a low-protein diet.

Advertisement

Unfortunately, most illnesses arent as simple or treatable. We are only at the beginning of our journey to understand the complexity of the human genome, and some of the information we have learned so far can create difficult dilemmas.

Take the genetic condition Huntingtons disease, which starts with mild symptoms in middle age, eventually progressing to severe disability and early death. There is no cure.

When people learn that Huntingtons is in their family, they may spend years deciding whether to take the test. Many choose not to. Parents who ask doctors to test their child are turned down, as set out in international guidelines. Deciding to learn if you have the gene responsible is such a personal choice that it must be left to the individual concerned once they turn 18.

Huntingtons is rare, but there are similar dilemmas over more common conditions such as genes that predispose people to Alzheimers disease and some types of cancer. There is currently little you can do to avoid dementia, and for women who learn they have a certain gene that increases cancer risk, the safest step is to have their breasts and ovaries removed.

Some people would rather not know about these risks before it is necessary. We have endless discussions about [the ethics of] testing children for conditions that dont manifest until later life, says Frances Elmslie of the British Society for Genetic Medicine.

Nor would it make sense to sequence children at birth then wait until they are 18 to give the results. In the intervening years, DNA sequencing is bound to become cheaper and more powerful. It would make more sense to offer it to every 18-year-old, says Martin Brunet, a family doctor in Surrey, UK.

There is a small group of children for whom genome sequencing can be useful: those with rare undiagnosed medical conditions. In one study, sequencing led to a diagnosis in a fifth of children in intensive care, and that figure is likely to improve over time. In these cases, parents can consent for their children because there is a medical benefit but that is very different to sequencing everyone out of curiosity.

A US group has begun a small trial of routine genome sequencing of healthy babies. The families are being monitored to see how they cope and to measure any harms and benefits.

No details are available about the UK plans and Hancock didnt respond to New Scientists requests for comment. But introducing sequencing for everyone is a massive step. It will require public consultation over the ethical questions not to mention on practical issues like how the data will be stored securely and the impact on doctors workloads, says Elmslie. We need to think really carefully about this.

More on these topics:

Read more:
Sequencing the genome of every UK baby would be an ethical minefield - New Scientist News

Read More...

Alzheimer’s disease: Rare genetic mutation might hold clues to preventing or treating dementia – CBS News

November 11th, 2019 11:41 am

Could one woman's rare genetic mutation one day have a global impact on dementia risk?

It's possible, say investigators who report on a potentially groundbreaking case of a woman whose genetic mutation staved off dementia for decades, even though her brain hadalreadybeen damaged by Alzheimer's disease.

While most Alzheimer's cases are not driven by genetic predisposition, one woman in Colombia is among about 1,200 in her country who do face a genetically higher risk for early-onset Alzheimer's.

Why? They all carry the E280A mutation of a gene called Presenilin 1 (PSEN1), which is known to increase the chances for Alzheimer's at a far younger age than usual.

"We identified an individual that was predisposed to develop Alzheimer's in her 40s," noted study author Dr. Joseph Arboleda-Velasquez. He's an assistant professor of ophthalmology with the Schepens Eye Research Institute of Mass Eye and Ear at Harvard Medical School, in Boston.

But, strangely, the woman "remained unimpaired until her 70s," Arboleda-Velasquez added.

The twist: the woman had, in fact, developed clear telltale signs of Alzheimer's in her brain. She just hadn't developed dementia.

For example, while she had fewer neural "tangles" in her brain than is typical for Alzheimer's patients, by the time she hit her 40s she did have the same unusually high level of brain amyloid-beta deposits as her E280A peers. Such deposits are a key signature of Alzheimer's.

So why didn't she develop middle-aged dementia like her peers?

To unravel the mystery, Arboleda-Velasquez and his colleagues ran an in-depth genetic analysis on the woman. And what they found is that she had not just one mutation, but two.

In addition to the E280A mutation, she also carried the so-called "Christchurch" mutation in the APOE3 gene.

But there's more. Not only did she carry the Christchurch mutation, but she hadtwoof them. Some of her E280A peers (about 6%) also carried a single copy of Christchurch. But she was the only one who carried two, the investigators found.

"It is ultra-rare, with an approximate prevalence of less than one in every 200,000 individuals," Arboleda-Velasquez said.

And having one such rare mutation did not appear to be enough. No protection against dementia was linked to only one Christchurch mutation. But as this woman's case suggests, having two such mutations did seem to throw up a shield against Alzheimer's, preserving her ability to remember things and think clearly for a few decades, long after her E280A peers had started experiencing cognitive decline.

"This is the first time a specific patient who carries the [double] mutation has been linked to such a protective benefit," Arboleda-Velasquez noted.

How does it work? It seems that "the mutation puts a block on the cascade of events linking amyloid accumulation to neural [brain cell] death," he explained.

The team did acknowledge that more research will be needed to definitively confirm the Christchurch mutation's impact, and to further explore how this mutation/dementia delay connection truly works.

But, in theory, the incredibly rare experience of this one woman in Colombia could ultimately have profound ramifications for Alzheimer's patients around the world, if "new drugs that mimic the effect of [the] mutation" could be developed, said Arboleda-Velasquez. Rather than stopping Alzheimer's from developing, such drugs would prevent Alzheimer's from causing dementia.

The study was published Nov. 4 in the journalNature Medicine, and was partly funded by the U.S. National Institutes of Health and the Alzheimer's Association.

Heather Snyder, vice president of medical and scientific relations at the Alzheimer's Association, characterized the findings as "an important discovery."

The insights gleaned from a look at this particular patient's experience are "full of possibilities for increasing our understanding of Alzheimer's disease and all dementia, and advancing potential avenues for treatment," Snyder suggested.

"Understanding what is happening in the brains of people when there appears to be a delay or stopping of the disease progression because of this gene form or otherwise gives rise to many possibilities for investigating new treatment and risk-reduction opportunities," she added.

At the same time, Snyder cautioned that "more research is needed to understand more thoroughly how genetics impacts Alzheimer's/dementia risk, and to expand and confirm these findings in a larger number of people."

Here is the original post:
Alzheimer's disease: Rare genetic mutation might hold clues to preventing or treating dementia - CBS News

Read More...

How Science And Technology Have Changed During ‘Morning Edition’ – NPR

November 11th, 2019 11:41 am

Cards representing AIDS victims are held aloft during a 1983 interdenominational service in New York's Central Park. Charles Ruppmann/NY Daily News via Getty Images hide caption

Cards representing AIDS victims are held aloft during a 1983 interdenominational service in New York's Central Park.

When Morning Edition first went on the air on Nov. 5, 1979, AIDS was an unknown acronym. And the ideas of a cloned mammal or a map of human DNA may as well have been science fiction.

But much has changed in the past four decades. During that time, spectacular advances across the scientific disciplines have had a major impact on the way we live today.

In 1981, Morning Edition aired a story about a strange set of cancers called Kaposi's sarcoma.

"In the last three months, 28 cases of Kaposi's sarcoma have been reported in this country, all occurring among gay men, most of them young," Laurie Garrett reported.

No one knew it at the time, but those cases were the first indication of the AIDS epidemic that was to come. And that story was the first mention of the disease on NPR.

At first, AIDS was largely viewed as a disease of gay people. But it was never only that, a fact that hit home to many people in 1991 when basketball star Earvin "Magic" Johnson who was married and heterosexual announced to the world that he was infected with HIV, the virus that causes AIDS.

When he made the announcement, Johnson also said he planned to live a long time, despite having the virus.

Many people were skeptical. HIV infection was frequently a death sentence in the early days of the epidemic.

But medical researchers had already found a few drugs that were helpful at keeping AIDS at bay, and now there are a bevy of options for treating HIV infection and AIDS. These days, HIV infection is typically a manageable disease and Johnson is still alive.

AIDS is just one of the diseases scientists have made progress controlling during the Morning Edition era. Now, parents can prevent many genetic diseases before a pregnancy is even begun. Genetic testing can ensure that only embryos not carrying a disease gene the cystic fibrosis gene, for example are implanted via IVF.

Almost all advances in genetic medicine rely heavily on a project to map and sequence all of the DNA in a human body.

But in 1986 when the idea was first proposed, many people, including many scientists, scoffed. Sequencing all 3 billion DNA base pairs in our 23 pairs of chromosomes was thought too Herculean a task.

A visitor views a digital representation of the human genome at the American Museum of Natural History in New York. Mario Tama/Getty Images hide caption

A few years later, the Human Genome Project was officially started, and in 2000, President Bill Clinton made this announcement at the White House:

"We are here to celebrate the completion of the first survey of the entire human genome. Without a doubt, this is the most important, most wondrous map ever produced by humankind."

Climate change is another topic that has been in the news for as long as Morning Edition has been on the air. As early as 1982, the show was reporting on scientists' concerns about what was then known as the greenhouse effect.

A researcher submerges his arm in melted Arctic ice in Barrow, Alaska. David L. Ryan/Boston Globe via Getty Images hide caption

"In the past year, scientists have presented evidence that the polar ice caps are slowly melting," Lili Francklyn reported in a story from that year. "And some researchers feel that we'll see climate changes within the next decade."

For a while, climate change seemed to be a nonpartisan issue. In 2008, Republican Newt Gingrich and Democrat Nancy Pelosi recorded a TV commercial together in which they say they "do agree our country must take action to address climate change."

But by 2017, that consensus had almost totally broken down. President Trump, who once famously called climate change a "hoax," announced that the United States would withdraw from the Paris Agreement that committed countries to taking steps to slow the rise of global temperatures. The U.S. formally requested withdrawal earlier this week.

Before the introduction of the personal computer, mainframe computers were the norm. The IBM System/370 mainframe computer, introduced in 1970, was one of the first computers to include "virtual memory" technology. Getty Images hide caption

Of all the transformative scientific advances in the past 40 years, perhaps the one that has affected the most lives is the rise of the Internet. Developed initially with support from the U.S. Department of Defense and then the National Science Foundation for national security and scientific research, the Internet now connects the world as never before.

When Morning Edition first went on the air, few people, if any, would have imagined that companies like Google, Facebook and Amazon would come to be part of the S&P 500. At the time, computers were mainly used by enthusiasts, scientists and engineers.

An announcement in 1981 from an industry executive signaled that computers were going mainstream.

"Well, today I'm pleased to tell you that we're introducing the IBM personal computer. It's a landmark announcement for our division and our company and we believe it will set a new standard for the industry," said George Conrades of IBM.

That people would carry small devices in their pockets capable of connecting them to the world would also have been unthinkable. Yet today more than 2 billion people own smartphones, and the number is growing rapidly around the world.

Indeed, when Morning Edition went on the air in 1979, you had to live near a broadcast tower in the United States in order to hear the program. Now you can tune in from a cafe in Kathmandu or a bar in Barcelona, and for that, you can thank the Internet.

See the rest here:
How Science And Technology Have Changed During 'Morning Edition' - NPR

Read More...

Page 819«..1020..818819820821..830840..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick